LeMaitre Vascular (NASDAQ:LMAT) Lowered to Hold Rating by Wall Street Zen

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report issued on Saturday.

LMAT has been the subject of a number of other reports. Freedom Capital upgraded LeMaitre Vascular to a “hold” rating in a report on Tuesday, March 31st. Weiss Ratings raised LeMaitre Vascular from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, May 20th. Zacks Research upgraded LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 13th. Citizens Jmp upped their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Finally, Roth Mkm reiterated a “buy” rating and set a $117.00 price target (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Performance

NASDAQ LMAT opened at $93.95 on Friday. LeMaitre Vascular has a 52-week low of $79.00 and a 52-week high of $118.01. The company has a fifty day moving average of $102.42 and a 200-day moving average of $96.35. The company has a market capitalization of $2.15 billion, a P/E ratio of 34.67, a P/E/G ratio of 2.61 and a beta of 0.54. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.68 EPS for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The business had revenue of $66.55 million for the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter in the prior year, the firm earned $0.48 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, equities research analysts predict that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Insider Activity

In other news, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $107.00, for a total value of $313,296.00. Following the transaction, the insider owned 3,749 shares in the company, valued at approximately $401,143. The trade was a 43.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $108.69, for a total value of $3,030,385.89. Following the completion of the sale, the chief executive officer directly owned 1,430,019 shares of the company’s stock, valued at approximately $155,428,765.11. This trade represents a 1.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is currently owned by insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock worth $131,547,000 after purchasing an additional 21,946 shares during the last quarter. Conestoga Capital Advisors LLC increased its stake in shares of LeMaitre Vascular by 3.6% in the first quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock worth $161,224,000 after buying an additional 51,825 shares during the period. First Trust Advisors LP raised its holdings in LeMaitre Vascular by 6.2% during the 1st quarter. First Trust Advisors LP now owns 998,071 shares of the medical instruments supplier’s stock valued at $108,959,000 after buying an additional 57,931 shares during the last quarter. State Street Corp raised its holdings in LeMaitre Vascular by 0.8% during the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after buying an additional 6,130 shares during the last quarter. Finally, Congress Asset Management Co. boosted its position in LeMaitre Vascular by 5.8% during the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the period. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.